Dr. Jan Chemnitz is a co-founder of PROVIREX. He has been one of the company’s managing directors since its founding and has driven its transition from a startup to a biotech company backed by Series A funding. As the company’s CSO, he is currently responsible for establishing clinical development and for the strategic direction of research and development.

He studied biochemistry and molecular biology in Jena. After earning his Ph.D. at the Leibniz Institute for Virology in Hamburg, he joined the Hauber Group as a postdoctoral researcher and was involved in the development of recombinase technology from the very beginning; he has now been working in the field of strategies for curing HIV for 20 years.